ChemoCentryx ContactSite Map
News & Events

Overview

Corporate Governance

Annual Reports

SEC Filings


Stock Information

Press Releases

Events & Presentations

contact Info

FAQs

Shareholder Tools

ChemoCentryx is a biopharmaceutical company focused exclusively on discovering, developing and commercializing orally-administered therapeutics to treat autoimmune diseases, inflammatory disorders and cancer. Our drug candidates target specific chemokines or chemo-attractant receptors, thereby blocking the inflammatory response driven by that particular chemokine while leaving the rest of the immune system unaffected. Our goal is to discover, develop and commercialize therapeutics with distinct advantages over currently marketed therapies in our disease areas of focus, thereby maximizing shareholder value.

Stock Chart
Stock price graph
     
Stock Quote
NASDAQ: CCXI
Price:
7.26
Change:
+ 0.05
Day High:
7.34
Day Low:
6.90
Volume:
16,700
11:33 AM ET on Apr 28, 2015
Delayed at least 20 minutes.
Provided by eSignal.

View all »   RSSRecent News

Apr 22, 2015
ChemoCentryx to Hold First Quarter 2015 Financial Results Conference Call on Wednesday, May 6, 2015

Apr 20, 2015
ChemoCentryx Initiates Clinical Trial of CCX872, Its Next-Generation, Orally Administered CCR2 Inhibitor, in Pancreatic Cancer

Mar 12, 2015
ChemoCentryx Reports Fourth Quarter 2014 Financial Results and Provides Corporate Update

View all »Events & Presentations

May 6, 2015 at 5:00 PM ET
ChemoCentryx, Inc. First Quarter 2015 Financial Results Conference Call

^ Return to Top